1996

Abstract

On 19 December 1997, the EC requested consultations with Canada in respect of the alleged lack of protection of inventions by Canada in the area of pharmaceuticals under the relevant provisions of the Canadian implementing legislation, in particular the Patent Act. The EC alleged that Canada’s legislation is not compatible with its obligations under the TRIPS Agreement, because it does not provide for the full protection of patented pharmaceutical inventions for the entire duration of the term of protection envisaged by Articles 27.1, 28 and 33 of the TRIPS Agreement.

Countries: Canada
Loading

Article metrics loading...

/content/reports/25189832/43
2000-03-17
2024-11-14
http://instance.metastore.ingenta.com/content/reports/25189832/43
Loading
  • Published online: 17 Mar 2000
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
aHR0cHM6Ly93d3cud3RvLWlsaWJyYXJ5Lm9yZy8K